Featured Research

from universities, journals, and other organizations

Targeted Therapy For Lung Cancer Patients Shows Promise In Extending Lives

Date:
June 23, 2004
Source:
Rush University Medical Center
Summary:
Oncologists at Rush University Medical Center, Chicago, are studying what they believe may be the wave of the future for treating patients with advanced stage lung cancer: individualized targeted therapy--easier than chemotherapy, more specialized and less toxic.

CHICAGO -- Oncologists at Rush University Medical Center, Chicago, are studying what they believe may be the wave of the future for treating patients with advanced stage lung cancer: individualized targeted therapy--easier than chemotherapy, more specialized and less toxic.

Related Articles


Dr. Philip D. Bonomi, director of the Division of Hematology-Oncology at Rush and principal investigator of the study, is testing whether the combination of Tarceva (erlotinib) and Celebrex (celecoxib) can shrink tumors, relieve symptoms and offer improvement and survival for patients with stage IV lung cancer.

This is the one of the first efforts involving the combination of two targeted therapies in the treatment of advanced lung cancer without chemotherapy. Molecular profiles on each patient’s tumor can be evaluated to see which patients might respond better.

"This therapy is being tested in patients who have already been treated with chemotherapy, have their disease progressing, and can provide tissue for profiling. We’ve recruited 10 patients so far, and expect to enroll 50 among the IV sites in the study."

Targeted therapy is based on the idea that a drug will attack its target without damaging other tissue. This combination therapy is better at focusing on abnormal signals that drive cancer cells, while sparing more of the body’s healthier cells. By blocking essential pathways within tumor cells, the therapy works inside of the cell with minimal effects on noncancerous cells. The drugs reduce the cancer by blocking the process by which cancer cells divide, grow and spread.

Bonomi says that Tarceva "aims to slow cancer growth by blocking the action of a molecule called the epidermal growth factor receptor, or EGFR, a protein found in the cell membrane of some cells, but found at an abnormally high rate in cancer cells. The protein triggers cells to divide at an accelerated rate, which allows the abnormal cancer cells to grow and spread.

"We hope that doing molecular profiling on each patient’s tumor will enable us to identify patients who are more likely to respond and to have a favorable response. We are looking to achieve tumor shrinkage with minimal side effects. We are hopeful that this type of research will provide a kinder, gentler, more effective therapy for lung cancer patients.

"This is the most exciting thing going on in lung cancer today. For the next two decades, this will be the wave of the future in treatment."

Patients with stage IV lung cancer who receive one course of chemotherapy have side effects of nausea, vomiting and can feel worn down. This two-pill combination is not chemotherapy, and it’s less toxic to the body; patients do not experience nausea and vomiting. The targeted therapy can help some patients feel better and live longer. The side effects of these pills, which are less bothersome than that of traditional chemotherapy, include an acne-like rash and diarrhea.

Bonomi says that such seriously ill lung cancer patients might be expected to live four to six months without treatment. Tarceva, one of the combination drugs, has recently been reported to increase survival. In general, survival improvement for patients with advanced stage lung cancer have been modest- adding several months to longevity. "And while that doesn’t seem like a lot of time, that may mean a lot to cancer patients planning to attend a graduation, anniversary or upcoming birthday in the next few months."

Over 170,000 new incidences of lung cancer are reported every year.

The other sites in the study are Rush North Shore, Skokie, Ill.; Northwestern Memorial Hospital, Chicago, and Vanderbilt University Medical Center, Nashville.

To enroll in the study, please call (312) 942-5687.


Story Source:

The above story is based on materials provided by Rush University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Rush University Medical Center. "Targeted Therapy For Lung Cancer Patients Shows Promise In Extending Lives." ScienceDaily. ScienceDaily, 23 June 2004. <www.sciencedaily.com/releases/2004/06/040623083437.htm>.
Rush University Medical Center. (2004, June 23). Targeted Therapy For Lung Cancer Patients Shows Promise In Extending Lives. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2004/06/040623083437.htm
Rush University Medical Center. "Targeted Therapy For Lung Cancer Patients Shows Promise In Extending Lives." ScienceDaily. www.sciencedaily.com/releases/2004/06/040623083437.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins